Kornimate/medical-research-clean huggingface dataset:
muscle energy technique and stretching exercise in working pregnant women with piriformis syndrome

Conditions: Piriformis Syndrome

Summary: piriformis syndrome is a neuro muscular disorder which occur due to the compression and irritation of the sciatic nerve by the piriformis muscle causing pain, tingling, and numbness in the buttocks and along the sciatic nerve. muscle energy technique is one of manual technique in which the muscle uses its own energy in the form of isometric contraction to relax the muscle by the autogenic inhibition of reciprocal inhibition. reciprocal inhibition in muscle energy technique was succeeded in relieving pain and improves flexibility.

piriformis syndrome is a neuro muscular disorder which occur due to the compression and irritation of the sciatic nerve by the piriformis muscle causing pain, tingling, and numbness in the buttocks and along the sciatic nerve. muscle energy technique is one of manual technique in which the muscle uses its own energy in the form of isometric contraction to relax the muscle by the autogenic inhibition of reciprocal inhibition. reciprocal inhibition in muscle energy technique was succeeded in relieving pain and improves flexibility. stretching exercises improves physical performance ability, prevents injury, reduces muscle pain and increases flexibility. both muscle energy technique and stretching has shown significant improvement in reducing pain and lower extremity function and increase range of motion. randomized clinical trial will be conducted. sample size of 30 patients will be taken. non probability convenient sampling will be used.a written consent form will be taken from participants meeting inclusion criteria and will be randomly allocated into two groups, to either the muscle energy technique group or stretching exercises group.treatment will be given twice a week for twelve treatment session..numeric pain rating scale will be used to measure the intensity of pain,lower extremity functional scale will be used to access lower extremity function. standard goniometer is used to measure hip joint range of motion.all participants in both groups will be evaluated before and after treatment programme.total duration of study will be six months.data will be analyzed by using spss 25. key words muscle energy technique,stretching exercises,piriformis syndrome,pain,range of motion

Eligibility criteria:
inclusion criteria: * age between 25-45 years . * tenderness of piriformis muscle. * chronic non-specific low back pain patients. * women in second trimester of pregnancy * multiparous women * slr positive below 60 degrees . * vas score: 6-10 * internal rotation of hip less than 45 degrees. exclusion criteria: * slr negative test * skin allergy * pre-eclampsia * gestational diabetes mellitus * clinical diagnosis of osteoarthritis or history of fracture of lower extremities

Keywords: muscle energy technique,stretching exercise, pain rom
dry cupping therapy in knee osteoarthritis

Conditions: Osteo Arthritis Knee; Pain, Chronic; Pain

Summary: introduction: knee osteoarthritis (koa) is the biggest cause of pain and disability worldwide. as a non-pharmacological approach, ventosatherapia has been used to control pain, improve function and quality of life. however, there is a lack of high-quality scientific evidence regarding its effects on this condition. objective: to evaluate the effects of dry cupping on pain, function and quality of life in women with koa. methods: this is a randomized, blinded placebo-controlled protocol. 62 women diagnosed with koa will be recruited, based on the clinical criteria of the american college of rheumatology, who will be randomly divided into two groups (31 per group): dry cupping and dry cupping sham.

the intervention will be carried out for 15 minutes, twice a week, for 6 consecutive weeks, totaling 12 sessions. both groups will be evaluated in 4 moments: before the intervention (t0), after 3 weeks of interventions (t3), at the end of the protocol (t6) and 4 weeks after the end of the interventions (follow-up - t10). the analyzed outcomes will be: primary - pain (numerical pain scale); secondary - physical function (womac; tests of going up / down stairs, brisk walking in 40 m and sitting / rising from a chair in 30 s), quality of life (sf-36) and global perception of the effect

Eligibility criteria:
inclusion criteria: * diagnosed with koa based on acr clinical criteria; * knee pain intensity between 3 and 8, according to the numerical pain scale (end); * bmi less than 35 kg / m2. exclusion criteria: * having undergone physical therapy treatment for the knee in the 3 months prior to the project; * be engaged in\> 45 minutes / week in accumulated physical activity of at least moderate intensity; * to have been submitted to the application and / or intervention with the wind therapy previously. * have used corticosteroid infiltration in the knee in the last 6 months; * present any medical restrictions that make it impossible for them to participate in the proposed assessments and interventions (cardiorespiratory, neurological and / or musculoskeletal changes); * presenting a diagnosis of fibromyalgia, rheumatoid arthritis or some systemic inflammatory arthritis; * presenting a ligament or meniscal injury diagnosed clinically or with a positive result in the apley tests or anterior / posterior drawer; * have had previous surgery on the ankle, knee or hip; * present a clinical diagnosis of some dementia or inability to answer the questionnaires related to the study; * present any contraindications for the use of ventosatherapia (skin lesion in the region where it will be applied, cancer, kidney failure, liver and heart failure, pacemaker, pregnancy); * having uncontrolled diabetes and hypertension; * have a trip scheduled for the two months following inclusion in the survey.

Keywords: chronic pain traditional chinese medicine complementary therapie
protein intake in patients with colorectal or lung cancer when receiving a nutritional supplement

Conditions: Colorectal Cancer; Lung Cancer

Summary: the proteos study is an randomized controlled, open label, parallel-group, multi-centre and multicounty interventional study to assess the acceptance and implementation of compact protein, a low volume, energy dense and high protein oral nutritional support in clinical practice according to the espen guidelines in colorectal and lung cancer patients undergoing chemo(radio)- or immunotherapy treatment.


Eligibility criteria:
inclusion criteria: * histologically proven crc stage iib, iii or iv or histologically or cytologically proven nsclc stage iii or iv * eligible and scheduled for first line chemotherapy, concurrent chemoradiotherapy or immunotherapy treatment with a planned duration of at least 12 weeks * performance status eastern cooperative oncology group (ecog) score 0 or 1 * age ≥ 18 years * written informed consent exclusion criteria: * scheduled for first line chemotherapy, concurrent chemoradiotherapy or immunotherapy treatment starting ≤4 days after randomization * received radiotherapy within 2 months prior to the study * weight loss \>10% in the last 6 months * body mass index \< 20.0 kg/m2 * life expectancy \< 3 months * prescription of oral nutritional supplementation (ons) before start of first line treatment based on hospital's standard practice * presence of ileostoma or ileal pouch * contra-indications to oral feeding, high protein nutrition or to the test product (including galactosaemia) in the opinion of the investigator * known pregnancy or lactation * current alcohol or drug abuse in the opinion of the investigator * investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements * participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study
gene polymorphisms and gene products as biological markers of aging and correlation with clinical geriatric assessment, tolerance of chemotherapy and outcome in elderly breast cancer patients

Conditions: Breast Cancer; Elderly

Summary: the goal is to study the biology of aging in breast cancer patients, and to study the impact of chemotherapy on aging related blood biomarkers.


Eligibility criteria:
inclusion criteria: * 70 years or older * female * early breast cancer * candidate for systemic adjuvant therapy

Keywords: breast cancer elderly biomarker
hand exoskeleton training study

Conditions: Stroke

Summary: the goal of this study is to evaluate the handmate device's effectiveness in the rehabilitation of stroke patients and asses if the handmate application is received well by stroke survivors. participants will use the handmate device in clinic and in the home. they will also complete clinical upper extremity assessments.

this study will evaluate the effectiveness of novel device and its potential to help stroke victims regain functional use of their hand and regain independent living. the study will also evaluate the potential of the device to be used at home, this would allow increased therapy intensity and decreased overall treatment costs (fewer therapist hours required and decreased travel costs).

Eligibility criteria:
inclusion criteria: * age of 21 or older * diagnosis of stroke more than 6 months prior confirmed from mri or ct * voluntary hand activity (score of 1 or more, finger extension item, fugl-meyer test) * adequate cognitive status * impaired ability to open affected hand exclusion criteria: * hemispatial neglect * severe sensory loss (2 or more on the sensory item, nih stroke scale/score) * receiving or planning to receive antispasticity medications during enrollment into the study * less than full passive range of motion in finger joints * receiving physical or occupational therapy outside of study protocols * have excessive pain in any joint of the affected extremity that could limit ability to cooperate with the protocols
whitening efficacy and tooth sensitivity of different concentrations of hydrogen peroxide photoactivated with violet or blue leds

Conditions: Color; Bleaching Sensitivity

Summary: this is a randomized, controlled, double-blind and repeated-measures clinical trial evaluated the photoactivation of hydrogen peroxide gels in different concentrations with blue or violet led in terms of whitening efficacy and tooth sensitivity.


Eligibility criteria:
inclusion criteria: * at age 18 or older, with good general and oral health; * possessing all six natural and healthy upper anterior teeth with a color shade of a2 or darker, determined by comparison with the vita classic scale; exclusion criteria: * pregnant and breastfeeding women; * individuals with internal tooth discoloration (tetracycline stains, fluorosis or hypoplasias); * smokers, or those with veneers or restorations on the teeth in questions were excluded; * gingival recession; * dentin exposure; * periodontal disease.
treatment patterns among patients with prostate cancer prior to diagnosis of a castration-resistant state

Conditions: Prostate Cancer

Summary: the purpose of the protocol is to describe treatment patterns among patients with prostate cancer prior to diagnosis of castration-resistant state.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients with prostate cancer who had developed a castration resistant state in the last 24 months prior to starting the study * patient must give written informed consent before any study related procedure exclusion criteria: * patients with medical histories lacking data required to evaluate the study objectives
real-world clinical outcomes of nsclc patients receiving neoadjuvant immunotherapy

Conditions: NSCLC

Summary: the goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of different neoadjuvant immunotherapies in non-small cell lung cancer (nsclc) patients using the real-world data. the main questions it aims to answer are: * what the best setting for immune checkpoint inhibitors as the neoadjuvant treatment? * how to determine the subgroups of patients benefit from neoadjuvant immunotherapy? participants will receive neoadjuvant immunotherapy the study will analyze the real-world data.

the objective of this observational study is to assess the effectiveness and long-term clinical outcomes of various neoadjuvant immunotherapies in patients with non-small cell lung cancer (nsclc), using the real-world data. the primary inquiries it seeks to address include: * what is the optimal strategy for utilizing immune checkpoint inhibitors as neoadjuvant therapy? * how can we identify specific patient subgroups that derive the greatest benefit from neoadjuvant immunotherapy? participants will undergo neoadjuvant immunotherapy, and the study will meticulously analyze real-world data to provide insights into these pivotal questions, contributing to the refinement of treatment strategies and patient care in nsclc management.

Eligibility criteria:
inclusion criteria: 1. histological diagnosis of non-small cell lung cancer (stage i-iv, international association for the study of lung cancer staging eighth edition) 2. patients who have previously undergone immune checkpoint inhibitors as the neoadjuvant treatment; 3. no previous history of malignant tumors and other malignant tumors at the same time, without any anti-tumor treatment; 4. eastern cooperative oncology group (ecog) score 0-1, heart, lung, liver, brain and kidney function can tolerate surgery; 5. at least one measurable lesion (recist v1.1). exclusion criteria: 1. patients included in unblinded clinical trials or anti-tumor drug intervention. 2. radiotherapy or systemic therapy were used for nsclc patients before the surgery.
multi-reader, multi-case, cross-over, retrospective study to evaluate effectiveness of lunit insight dbt

Conditions: Breast Cancer

Summary: this study aims to evaluate effectiveness of lunit insight dbt in the assistance of detection and diagnosis of breast cancer during 3d mammography interpretation

the primary objective of the trial is to evaluate the effectiveness of lunit insight dbt in the assistance of detection and diagnosis of breast cancer by comparing the clinical performance of radiologists before and after using lunit insight dbt in their dbt reading and secondarily examining the use of lunit insight dbt to shorten dbt reading time.

Eligibility criteria:
inclusion criteria: \[for all subject groups\] * female * 22 years old or older \[for 'control (non-cancer)' group\] * negative cases interpreted as bi-rads 0 (assessment incomplete) or bi-rads 1 (negative) with no cancers on the dbt exam and confirmed as bi-rads 1 (negative) on the further diagnostic imaging (e.g., mmg, dbt, mri, ct and ultrasound) taken at least after 1 year of the dbt exam. * benign cases interpreted as bi-rads 0 (assessment incomplete) or bi-rads 2 (benign) with a visible lesion on the dbt exam and confirmed as bi-rads 2 (benign) on the further diagnostic imaging (e.g., mmg, dbt, mri, ct and ultrasound) taken at least after 1 year of the dbt exam without a further breast biopsy. or for the biopsy-proven benign exams, interpreted as bi-rads 0 (assessment incomplete), bi-rads 3 (probably benign), 4 (suspicious) or 5 (highly suggestive of malignancy) with a visible suspicious lesion for breast cancer on the dbt exam but confirmed as benign through subsequent biopsy conducted within following 1 year of the dbt exam. \[for 'condition (cancer)' group\] interpreted as bi-rads 0 (assessment incomplete), bi-rads 3 (probably benign), 4 (suspicious) or 5 (highly suggestive of malignancy) with a visible suspicious lesion for breast cancer on the dbt exam and confirmed as a cancer (malignant) through the subsequent biopsy conducted within following 1 year of the dbt exam. exclusion criteria: * previous breast cancer * previous vacuum-assisted biopsy, surgical biopsy or surgery in breast * presence of a breast implant or pacemaker on the required images: 4 views (rcc, rmlo, lcc, lmlo) images of screening or diagnostic dbt exams with a ffdm (full-field digital mammography) image or with a synthetic 2d image
transesophageal echocardiography to diagnose blunt traumatic aortic injury traumatic aortic injury

Conditions: Trauma Chest

Summary: to determine test performance of transesophageal echocardiography performed by emergency physician ultrasound for the identification of blunt traumatic aortic injury in chest trauma.

this is a multicentre prospective observational trial. all trauma patients with suspected btai at the emergency department (ed) will undergo resuscitative transesophageal echocardiography to evaluate the thoracic aorta. resuscitative tee is a minimally invasive procedure to evaluate all chest trauma patients. besides the aorta, tee can also provide other useful information regarding the hemodynamic status, cardiac function and lung pathology of the patient. patients will be recruited into the study by investigators who take informed consent from the patient or next of kin prior to the tee procedure. for all patients with suspected btai, cta is mandatory to confirm the diagnosis of btai. tee findings of btai will be compared to cta which will be considered the reference standard unless confirmation is available from surgical procedures or autopsy. inter-observer variability for normal or pathological tee images interpretation is performed prior to the initiation of the study.

Eligibility criteria:
inclusion criteria: all trauma patients with suspected btai in the emergency department (ed) who undergo both tee and cta. exclusion criteria: 1. children (age under 18 years) will not be eligible for inclusion in this study. 2. patients with contraindication to tee such as suspected esophageal injury or pathology

Keywords: transesophageal echocardiography aorta trauma emergency department blunt trauma
xolair (omalizumab) for treatment of drug-induced acute tubulointerstitial nephritis (ain)

Conditions: Acute Interstitial Nephritis

Summary: the investigators goal is to evaluate the role of xolair® in treatment of acute tubulointerstitial nephritis (ain) with the goal of shortening the duration and dose of prednisone for treatment of drug-induced ain. currently there is no good treatment for drug-induced ain. prednisone is the standard treatment but is associated with many side-effects when used long-term and at high doses.


Eligibility criteria:
inclusion criteria: 1. adult subjects \> 18 years old of both genders 2. biopsy proven acute interstitial nephritis in the native kidneys without evidence of ischemic or glomerular pathology in the biopsy 3. normal baseline creatinine defined as estimated gfr ≥ 60 ml/min/sa based on mdrd calculation within 1 year prior to renal biopsy 4. serum creatinine elevation of \> 0.3 mg/dl and/or doubling of serum creatinine compared to most recent documented creatinine available (at least within the last year) 5. no immunosuppressants in the last three months including prednisone 6. women of childbearing potential not using the contraception method can be included as this is a one time dosing and has no known long-term effects. exclusion criteria: 1. unwillingness to give consent 2. patients who are pregnant (positive serum pregnancy test for females) or breast feeding 3. documented history of an autoimmune disease 4. inability or unwillingness to take prednisone for the prescribed duration and/or dose 5. subjects suspected to have non-drug-induced ain 6. subjects not meeting the inclusion criteria 7. subjects with contraindication to administration of omalizumab 8. prior use of omalizumab 9. severe hypersensitivity to omalizumab or any component of the product 10. known elevated ige level from other disease processes 11. subjects taking (nonsteroidal antiinflammatory drug) nsaids chronically 12. use of any other investigational agents in the last 30 days 13. patients with severe medical condition(s) including metastatic cancer, terminal congestive heart failure, severe ischemic heart disease or any other medical condition in which life expectancy is less than 6 months.

Keywords: interstitial nephritis nephritis tubulointerstitial renal disease kidney
rwd study in her2+ mbc patients in third-line therapy

Conditions: Breast Cancer Stage IV

Summary: this retrospective observational study will collect canadian real-world data (rwd) from her2+ metastatic breast cancer (mbc) patients to describe treatment sequences of all therapies received in the metastatic setting, to measure overall survival (os), progression free survival (pfs), time to next active anti-cancer therapy, and to estimate the health resources utilization (hru) during third-line therapy.

the proportion of treatment received during all lines of therapy in the metastatic setting will be described. the 2-year survival rate and median os with interquartile range (iqr) for third-line therapy will be calculated. hru data and costs during third-line therapy will be collected.

Eligibility criteria:
inclusion criteria: male or female patients (≥18 years of age) patients with stage iv breast cancer patients with her2+ status in metastatic setting patients that received at least two lines of active anti-cancer drugs due to disease progression. patients that began third-line therapy prior to october 31, 2018. exclusion criteria: patients treated with an investigational anticancer agent in the ≥ 3rd line setting

Keywords: her2 positive real world data metastatic breast cancer real world evidence
evaluation of the microcirculation during the corrective surgery of congenital heart defects in children

Conditions: Congenital Heart Disease

Summary: general objective of the research project: to evaluate the alterations of systemic microvascular reactivity during cardiopulmonary bypass (cpb), in children submitted to cardiac surgery for repair of congenital heart defects.

• specific objectives: * to test the usefulness of skin laser doppler flowmetry monitoring (ldpm) in the non-invasive evaluation of endothelium-dependent microvascular reactivity during cpb in children. * to investigate whether skin ldpm could be proposed as a clinical monitoring of tissue perfusion during cpb in pediatric cardiac surgery. * to investigate the effects of different anesthetic agents on microvascular reactivity during cpb. * to investigate the effects of cardiovascular and vasoactive drugs used during cpb on microvascular reactivity. * to evaluate the correlation of microcirculatory alterations observed during cpb with classical markers of tissue perfusion and oxygenation, including plasma lactate levels. * to evaluate the correlation of microcirculatory alterations observed during cpb with markers of systemic inflammation, including pro- and anti-inflammatory cytokines. * to evaluate the correlation of microcirculatory alterations observed during cpb with the plasma bioavailability of nitric oxide.

Eligibility criteria:
inclusion criteria: * infants and children with congenital heart defects scheduled to corrective cardiac surgery exclusion criteria: * age inferior to 3 months and superior to 6 years

Keywords: congenital heart defects systemic microcirculation laser doppler perfusion imaging cardiac corrective surgery